RE: JAKs for Vovid2 May 2020 10:51
Stoney I agree with you kinase inhibiting molecules and inhibiting the right IL’s in what nature of inflammation whether it by lupus, Crohn's disease, RA, asthma and viral bacteria infections, JAK family inhibitors looks probably the best way forward for treatment, I guess there’s not a one size fits all JAK inhibitor, and the molecule tailored for each indication, in Num4 article it suggests treatment for covid-19 that each persons inflammation could be treated differently but the JAK inhibitors showing the most promise is when oxygen is needed!
“JAK inhibitors may be a better fit for hospitalised patients with symptoms indicative of hyperinflammation-driven pathology, Espinosa added. The ideal slot for JAK inhibition is hospitalised patients who require oxygen when the cytokine storm can still potentially be eased, said Benfield”
I do hope more research is presented for Tyk2 inhibiting ie Tim suggesting other Interleukins involved with elivated levels, this publication is pro IL-6 and why all the JAK inhibitors they mentions provide scientific rationale to be used against covid19!
But then it does state that IL-6 may not be the only Interleukin that needs inhibiting!
“While IL-6 is a logical candidate in easing inflammation, inhibiting it specifically at a higher potency such as with mAbs may not be ideal, as IL-6 could have other functions important in impacting the virus’ life cycle, García-Donas noted. IL-6 may also not be the most important aspect of a cytokine storm, Schett said.”
So I do hope that Tim’s suggestions in the presentation of inhibiting the other Interleukin can have some scientific back up from other scientists and publications because I think there’s only that one article that they tweeted from 2017, but Tyk2 is in early clinical research and no pre clinical data for the covid19 cykotine storms, so this could be the start to Tyk2 involvement for this!
It mentions in the article that Tyk2 is more targeting IL-12 and IL-20 and it don’t know if they are not looking for Tyk2 as a solution because they is no put forward molecules by the pharmaceutical companies to do so as I would want Pfizer to put their JAK1/TYK2 for a solution, it would be better!
“TYK2, the fourth JAK, is more linked with IL-12 and IL-20, which are not typically a part of CSS, he added.”
They do suggest in article that JAK1/JAK2 is the rationale, but on the other hand Tim has said that TYK2 can be a safer replacement for the uncertainty of toxic issues that JAK2 causes, so I hope it can be a replacement for JAK2!
“However, not all JAK inhibitors have the same targets, Schett said. Inhibiting JAKs 1 and 2 may be the most critical of the four JAKs, he noted. JAKs 1 and 2 are important in IL-6 generation, explained Espinosa”
Sign In
Follow the stocks
